Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Andromachi Giannopoulou"'
Publikováno v:
Pulmonary Therapy, Vol 9, Iss 3, Pp 435-450 (2023)
Abstract Introduction Understanding of the patient-perceived symptom burden of small cell lung cancer (SCLC) is limited. The objective of this study was to explore patients’ experiences with SCLC, identify which treatment-/disease-related symptoms
Externí odkaz:
https://doaj.org/article/8317d390659f4377b1ef8a86db66a285
Autor:
Amanda, Tufman, Kathy, Redmond, Andromachi, Giannopoulou, Sebastian, Gonzalez-McQuire, Pasquale, Varriale, Lena, Geltenbort-Rost, Katarina, Öhrling, Matthias, Scheffler
Publikováno v:
Lung Cancer. 168:59-66
To understand European non-small cell lung cancer (NSCLC) patients' perceptions of disease burden, treatment, and future expectations of treatment and care.A 32-item online survey was conducted on a sample of NSCLC patients across Europe. Descriptive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c54c810fca94a8a27a3bdce9541933b
https://doi.org/10.1016/j.lungcan.2022.04.008
https://doi.org/10.1016/j.lungcan.2022.04.008
Autor:
Sumeet Panjabi, Andrzej Jakubowiak, Eszter Tichy, Ivan Houisse, Marco Campioni, Sanjay K. Aggarwal, Beth Barber, Ágnes Benedict, Andromachi Giannopoulou
Publikováno v:
Journal of Medical Economics. 19:1061-1074
To assess the economic value of carfilzomib (Kyprolis), this study developed the Kyprolis Global Economic Model (K-GEM), which examined from a United States (US) payer perspective the cost-effectiveness of carfilzomib-lenalidomide-dexamethasone (KRd)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdba37594228dd87a10897df8609e93b
https://doi.org/10.1080/13696998.2016.1194278
https://doi.org/10.1080/13696998.2016.1194278
Autor:
Sanjay K. Aggarwal, Andromachi Giannopoulou, Andrzej Jakubowiak, Rafael Fonseca, Marco Campioni, Sumeet Panjabi, Ivan Houisse, Agnes Benedict
Publikováno v:
Journal of Clinical Oncology. 34:8021-8021
8021Background: In ASPIRE, KRd achieved superior progression free survival (PFS) (HR = 0.69; p = 0.0001) and improved quality of life (QoL) (p < 0.001) over Rd in patients (pts) with R/RMM. We asse...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11c11e4413554cd211066605e6f43ec5
https://doi.org/10.1200/jco.2016.34.15_suppl.8021
https://doi.org/10.1200/jco.2016.34.15_suppl.8021